[CAS NO. 19387-91-8] Tinidazole
PRODUCTS SPECIFICATIONS [19387-91-8]
DESCRIPTION [19387-91-8]
Overview
| MDL | MFCD00057217 |
|---|---|
| Molecular Weight | 247.27 |
| Molecular Formula | C8H13N3O4S |
| SMILES | CC1=NC=C([N+]([O-])=O)N1CCS(=O)(CC)=O |
Summary
Tinidazole, an orally available antibacterial agent, is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa [1] .
In Vitro
Tinidazole is one of the most active antibacterial agents against Bacteroides fragilis which is one of the most resistant species of anaerobic bacteria. Tinidazole is efficacious in protozoal infections such as trichomonal vaginitis, amoebiasis and giardiasis [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04132479 | Kirby Institute|University of Medicine 2, Yangon, Myanmar |
Helicobacter Pylori Infection
|
January 1, 2018 | Phase 4 |
| NCT03412071 | University of Toronto|UVRI-IAVI HIV Vaccine Program|Entebbe General Hospital |
Foreskin HIV Susceptibility
|
December 7, 2017 | Not Applicable |
| NCT00510614 | University of Pittsburgh|Mission Pharmacal |
Bacterial Vaginosis
|
October 2007 | Early Phase 1 |
| NCT01481844 | Soroka University Medical Center |
Optimization of Second Line Treatment Protocol for H Pylori Eradication
|
November 2011 | Phase 3 |
| NCT00403364 | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
Helicobacter Pylori Infection
|
July 2003 | Phase 2|Phase 3 |
| NCT01591889 | Roxane Laboratories|West-Ward Pharmaceutical |
Trichomoniasis
|
September 2009 | Phase 1 |
| NCT04264663 | Shandong University |
Helicobacter Pylori Infection
|
November 1, 2019 | Phase 4 |
| NCT04122287 | Shandong University |
Helicobacter Pylori Infection
|
November 1, 2019 | Phase 4 |
| NCT02988089 | Shandong University|Shandong Provincial Hospital|General Hospital of Jinan Military Region|Binzhou People´s Hospital|Liaocheng People´s Hospital |
Helicobacter Pylori Infection|Antimicrobial Susceptibility Testing
|
April 20, 2017 | Phase 4 |
| NCT02942485 | Helsinki University Central Hospital |
GIARDIASIS
|
December 1, 2016 | Phase 4 |
| NCT00322465 | National Institute of Allergy and Infectious Diseases (NIAID) |
Urethritis
|
November 2006 | Phase 2 |
| NCT03139253 | Yanqing Li|Shandong University |
Antimicrobial Susceptibility Testing|Triple Therapy
|
May 30, 2017 | Phase 4 |
| NCT01070277 | Sheba Medical Center |
Chronic Diarrhea|Abdominal Pain|Bloating
|
March 2012 | Not Applicable |
| NCT00787553 | University of Campinas, Brazil |
Hysterectomy
|
July 2006 | Not Applicable |
| NCT04652284 | Rabin Medical Center |
Helicobacter Infections|Resistance Bacterial|Gastritis H Pylori
|
May 1, 2021 | Phase 3 |
| NCT00229216 | Mission Pharmacal |
Bacterial Vaginosis
|
January 2005 | Phase 3 |
| NCT05383521 | Shangrong Fan|Peking University Shenzhen Hospital |
Trichomonas Vaginitis
|
December 1, 2022 | Not Applicable |
| NCT00324142 | Kaiser Permanente |
Recurrent Bacterial Vaginosis
|
Phase 2 | |
| NCT00003617 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Gastric Cancer
|
March 1995 | Phase 3 |
| NCT00811096 | Walter Reed Army Institute of Research (WRAIR) |
Malaria, Vivax
|
November 2008 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 50 mg/mL ( 202.21 mM )
H 2 O : 3.33 mg/mL ( 13.47 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.0442 mL | 20.2208 mL | 40.4416 mL |
| 5 mM | 0.8088 mL | 4.0442 mL | 8.0883 mL |
| 10 mM | 0.4044 mL | 2.0221 mL | 4.0442 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3.25 mg/mL (13.14 mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3.25 mg/mL (13.14 mM); Clear solution
-
4.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (8.09 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Synonyms